Alliance for Patient Medication Safety (APMS

to be fully published. While the safety and efficacy of voclosporin has been documented through recent studies, long-term outcomes have yet to be reported. Furthermore, these trials reveal voclosporin is superior only to placebo and background immunosuppressive therapy; therefore, future studies are necessary to determine its efficacy when compared to other calcineurin inhibitors and its usability in the treatment of active lupus nephritis.

Authors: Dr. Lindsey Benavent is a PGY-1 Resident at Novant Health New Hanover Regional Medical Center and Dylan King is a P-4 PharmD Candidate at Campbell University College of Pharmacy, dmking0617@email. campbell.edu.

Bibliography

1. Lupkynis [package insert]. Rockville,

MD: Aurinia Pharma US, Inc; 2021. 2. Lexi-Drugs. Lexicomp Online [database online]. Hudson, OH: Lexicomp, Inc. http://online.lexi.com. Updated 2021.

Accessed February 16, 2021. 3. Rovin BH, Solomons N, Pendergraft WF 3rd, et al. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.Kidney Int. 2019;95(1):219-231. doi:10.1016/j.kint.2018.08.025 4. ArriensC,PolyakovaS,AdzerikhoI, et al.

OP0277 AURORA phase 3 study demonstrates voclosporin statistical superiority over standard of care in lupus nephritis. Annals of the Rheumatic Diseases2020;79:172-173. Abstract. 5. Rovin BH, Teng YK, Ginzler EM, et al.

Efficacy and safety of voclosporin versus placebo for LUPUS nephritis (AURORA 1): A double-blind, randomized, multicenter, placebo-controlled, Phase 3 trial.

The Lancet. 2021;397(10289):20702080. doi:10.1016/s01406736(21)00578-x.